TBI identification and monitoring through retinal scanning

通过视网膜扫描进行 TBI 识别和监测

• 批准号: 10383172
• 负责人: LEE E. GOLDSTEIN
• 金额: $ 51.75万
• 依托单位: REBISCAN, LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10383172
• 关键词: Achievement; Acute; Affect; Age; Biological Markers; Blood; Blood Tests; Brain; Brain Injuries; Caring; Cessation of life; Clinical; Data; Development; Devices; Diagnosis; Dropout; Enrollment; Environment; Eye; Foundations; Funding; Grant; Head; Healthcare Systems; Individual; Injury; Intervention; Learning; Measures; Methods; Modification; Monitor; Neurocognitive; Outcome; Output; Paper; Participant; Patients; Performance; Phase; Procedures; Process; Provider; Recording of previous events; Recovery; Reporting; Retina; Risk; Running; Saccades; Scanning; Signal Transduction; Sorting - Cell Movement; Speed; Statistical Data Interpretation; Stimulus; Study Subject; Symptoms; Technology; Testing; Time; Trauma; Traumatic Brain Injury; Traumatic Brain Injury recovery; United States; Vision; Visit; Visual Pathways; Volition; Wisconsin; Work; base; blood-based biomarker; brain pathway; chronic traumatic encephalopathy; clinical examination; design; disability; experience; functional disability; gaze; healing; human subject; mild traumatic brain injury; millisecond; neurocognitive test; neuropsychiatric disorder; phase 2 study; polarized light; portability; preservation; prevent; programs; recruit; research clinical testing; response; sample fixation; success; tool; visual tracking

Project Summary/Abstract Rebion has produced a portable device – with support from NS117553 – that shows potential for serving as a tool that can identify functional impairment as a result of TBI. The device uses a retinal scan to measure disruptions between the retina and the visual pathway of the brain. The long-term vision of this work is to develop a tool that can serve as a functional assessment of injury at the time of injury, as well as during recovery, and to be paired with currently-available blood-based biomarkers to provide a comprehensive report for patients and providers. The device’s approach, unlike eye-tracking or any other available eye technology, is to assess the quality of signals between the retina and the brain. Accurate monitoring of function and overall recovery from TBI are underserved problems in the healthcare system that Rebion is seeking to help solve. TBI (traumatic brain injury) is the leading cause of long-term disability and death for individuals under the age of 45. Over 2.5 million cases of TBI are reported each year in the United States, with ~3-5 million individuals living with TBI-related disabilities. About 75% of patients diagnosed with TBI are classified as mTBI, which can be difficult to diagnose, as history is often incomplete and symptoms are nonspecific and overlap with a broad range of neuropsychiatric disorders. Although most patients with mTBI make a full recovery, as many as 20% do not. These are the patients that Rebion is ultimately focused on helping. Individuals who experience multiple mTBI are at increased risk of persistent post-injury symptoms and long-term complications, including serious sequelae such as chronic traumatic encephalopathy (CTE). Simple interventions such as removing the patient from risky environments may prevent these complications by allowing time for the brain to heal and preventing further injury. Grant support is being requested to support a human-subject study which will compare the Rebion device to a battery of clinical tests – blood biomarkers and neurocognitive assessments – in participants suspected of TBI. Pilot data collected to-date shows promise that this rapid, non-invasive method can serve a useful purpose in the patient’s journey through TBI.

项目概要/摘要 Rebion 在 NS117553 的支持下生产了一款便携式设备，显示出作为 可以识别 TBI 导致的功能障碍的工具。该设备使用视网膜扫描来测量 视网膜和大脑视觉通路之间的干扰。这项工作的长期愿景是 开发一种工具，可以在受伤时以及受伤期间对受伤进行功能评估 恢复，并与当前可用的血液生物标志物配对，提供全面的报告 对于患者和提供者。与眼动追踪或任何其他可用的眼部技术不同，该设备的方法是 评估视网膜和大脑之间的信号质量。准确监测功能和整体 TBI 后的恢复是医疗保健系统中服务不足的问题，Rebion 正在寻求帮助解决。 TBI（创伤性脑损伤）是 1 岁以下个体长期残疾和死亡的主要原因 45. 美国每年报告超过 250 万例 TBI 病例，约有 3-500 万人 患有与 TBI 相关的残疾。大约 75% 被诊断为 TBI 的患者被归类为 mTBI，这可以 很难诊断，因为病史往往不完整，症状不具有特异性，并且与广泛的疾病重叠 一系列神经精神疾病。尽管大多数 mTBI 患者都能完全康复，但仍有多达 20% 不要。这些是 Rebion 最终重点帮助的患者。经历过的个人 多次 mTBI 出现持续性损伤后症状和长期并发症的风险增加，包括 严重的后遗症，如慢性创伤性脑病（CTE）。简单的干预措施，例如删除 来自危险环境的患者可以通过让大脑有时间愈合和预防这些并发症 防止进一步受伤。 正在请求拨款支持以支持一项人体研究，该研究将 Rebion 设备与 对疑似 TBI 的参与者进行一系列临床测试——血液生物标志物和神经认知评估。 迄今为止收集的试点数据表明，这种快速、非侵入性的方法可以在以下方面发挥有用的作用： 患者经历 TBI 的过程。